Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

The histone deacetylase inhibitor suberoylanilide hydroxamic acid attenuates human astrocyte neurotoxicity induced by interferon-γ.

Hashioka S, Klegeris A, McGeer PL.

J Neuroinflammation. 2012 May 30;9:113. doi: 10.1186/1742-2094-9-113.

2.

STAT3 inhibitors attenuate interferon-γ-induced neurotoxicity and inflammatory molecule production by human astrocytes.

Hashioka S, Klegeris A, Qing H, McGeer PL.

Neurobiol Dis. 2011 Feb;41(2):299-307. doi: 10.1016/j.nbd.2010.09.018. Epub 2010 Oct 1.

PMID:
20888416
3.

Proton pump inhibitors reduce interferon-γ-induced neurotoxicity and STAT3 phosphorylation of human astrocytes.

Hashioka S, Klegeris A, McGeer PL.

Glia. 2011 May;59(5):833-40. doi: 10.1002/glia.21157. Epub 2011 Feb 28.

PMID:
21360757
4.

Inhibition of human astrocyte and microglia neurotoxicity by calcium channel blockers.

Hashioka S, Klegeris A, McGeer PL.

Neuropharmacology. 2012 Sep;63(4):685-91. doi: 10.1016/j.neuropharm.2012.05.033. Epub 2012 May 30.

PMID:
22659089
5.

The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines.

Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P, Donà G, Fossati G, Sozzani S, Azam T, Bufler P, Fantuzzi G, Goncharov I, Kim SH, Pomerantz BJ, Reznikov LL, Siegmund B, Dinarello CA, Mascagni P.

Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2995-3000. Epub 2002 Feb 26.

6.

Histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits anti-inflammatory activities through induction of mitochondrial damage and apoptosis in activated lymphocytes.

Shi ZJ, Ouyang DY, Zhu JS, Xu LH, He XH.

Int Immunopharmacol. 2012 Apr;12(4):580-7. doi: 10.1016/j.intimp.2012.02.005. Epub 2012 Feb 25.

PMID:
22369900
7.
11.

Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation.

Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB.

J Biol Chem. 2006 Mar 3;281(9):5612-22. Epub 2005 Dec 23.

12.

The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.

Shi YK, Li ZH, Han XQ, Yi JH, Wang ZH, Hou JL, Feng CR, Fang QH, Wang HH, Zhang PF, Wang FS, Shen J, Wang P.

Cancer Chemother Pharmacol. 2010 Nov;66(6):1131-40. doi: 10.1007/s00280-010-1455-1. Epub 2010 Sep 14.

PMID:
20838997
13.

Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.

Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM.

Cancer Res. 2000 Sep 15;60(18):5165-70.

14.

Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid.

Reilly CM, Mishra N, Miller JM, Joshi D, Ruiz P, Richon VM, Marks PA, Gilkeson GS.

J Immunol. 2004 Sep 15;173(6):4171-8.

15.

Interferon-gamma-dependent cytotoxic activation of human astrocytes and astrocytoma cells.

Hashioka S, Klegeris A, Schwab C, McGeer PL.

Neurobiol Aging. 2009 Dec;30(12):1924-35. doi: 10.1016/j.neurobiolaging.2008.02.019. Epub 2008 Mar 28.

PMID:
18375019
16.

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.

Yin D, Ong JM, Hu J, Desmond JC, Kawamata N, Konda BM, Black KL, Koeffler HP.

Clin Cancer Res. 2007 Feb 1;13(3):1045-52.

17.

Interleukin-10 inhibits interferon-gamma-induced intercellular adhesion molecule-1 gene transcription in human monocytes.

Song S, Ling-Hu H, Roebuck KA, Rabbi MF, Donnelly RP, Finnegan A.

Blood. 1997 Jun 15;89(12):4461-9.

18.

Interferon-γ-induced neurotoxicity of human astrocytes.

Hashioka S, McGeer EG, Miyaoka T, Wake R, Horiguchi J, McGeer PL.

CNS Neurol Disord Drug Targets. 2015;14(2):251-6. Review.

PMID:
25687700
19.

Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.

Häcker S, Dittrich A, Mohr A, Schweitzer T, Rutkowski S, Krauss J, Debatin KM, Fulda S.

Oncogene. 2009 Sep 3;28(35):3097-110. doi: 10.1038/onc.2009.161. Epub 2009 Jul 13.

PMID:
19597472

Supplemental Content

Support Center